Clinical Sales Specialist (CS) - Baltimore North at Corcept Therapeutics

Baltimore, Maryland, United States

Apply Now

$140,000 – $155,000Compensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

NoVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

BA/BS or equivalent work experience
5+ years of sales experience required
Recent experience in endocrine relationships, specialty therapeutic, hospital, or orphan drugs sales is highly preferred
Proven track record of consistent high performance
Strong ability to collaborate and work cross-functionally
Willingness to travel up to 100% of the time, including up to 40% overnight travel
Ability to lift and/or move up to 35 pounds
Currently authorized to work in the United States on a full-time basis

Responsibilities

Build and develop professional relationships with influential high prescribers and thought leaders in the assigned territory
Leverage expertise to anticipate and effectively manage business opportunities and challenges within the therapeutic disease state, marketplace, and industry
Develop and implement effective customer-specific territory plans and communicate insights to internal stakeholders
Prioritize time and effort to ensure optimal coverage of appropriate physician specialists
Plan and participate in education programs and speaker dinner programs
Manage territory expenses/budget to support sales and marketing activities

Skills

Pharmaceutical Sales

Endocrine Sales

Specialty Therapeutics Sales

Orphan Drugs Sales

Hospital Sales

Territory Management

Relationship Building

Sales Strategy

Cross-functional Collaboration

Physician Engagement

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free